Reversine: A Potent Aurora Kinase Inhibitor for Cancer Cell Research

Executive Summary: Reversine (A3760) is a cell-permeable small molecule that selectively inhibits Aurora kinases A, B, and C with nanomolar potency, impeding mitotic checkpoint function and cell cycle progression in tumor models (ApexBio). It is water-insoluble but dissolves in DMSO (≥19.65 mg/mL) and ethanol (≥6.69 mg/mL with warming and sonication), making it suitable for cell-based assays under controlled conditions (ApexBio). Reversine triggers dedifferentiation of murine myoblasts and induces apoptosis in multiple cervical cancer cell lines, both in vitro and in vivo (Kaisari et al., 2019). When combined with aspirin, reversine synergistically reduces tumor burden in murine cervical cancer models via enhanced apoptosis. Reversine is intended exclusively for research use, not for diagnostic or therapeutic applications.

Biological Rationale

Aurora kinases are serine/threonine kinases essential for accurate mitotic progression and chromosome segregation. Their activity regulates centrosome maturation, bipolar spindle assembly, and chromosome alignment (Kaisari et al., 2019). Dysregulation of Aurora kinase signaling is implicated in oncogenesis and chromosomal instability. Targeting these kinases offers a strategy to disrupt aberrant cell division in cancer cells. Reversine acts as a pan-Aurora kinase inhibitor, enabling researchers to dissect mitotic checkpoints and cell cycle regulation in cancer models (see also—this article further details workflow parameters and comparative model systems beyond prior reviews).

Mechanism of Action of Reversine

Reversine (6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine) competitively inhibits ATP binding at the catalytic sites of Aurora kinases A (IC₅₀: 150 nM), B (IC₅₀: 500 nM), and C (IC₅₀: 400 nM) (ApexBio). Aurora kinase inhibition impairs mitotic checkpoint signaling, leading to spindle defects, failed chromosome alignment, and premature anaphase onset. Inhibition of Aurora B, in particular, disrupts the phosphorylation of histone H3 (Ser10) and abrogates the spindle assembly checkpoint. Reversine-induced mitotic errors promote apoptosis or cell cycle arrest in susceptible cancer cells. In murine myoblasts, reversine can induce dedifferentiation, indicating its role in modulating cell fate decisions.

Evidence & Benchmarks

• Reversine inhibits Aurora kinase A with an IC₅₀ of 150 nM, B at 500 nM, and C at 400 nM under biochemical assay conditions (pH 7.5, 25°C) (ApexBio).
• In vitro, reversine suppresses proliferation and induces apoptosis in HeLa, U14, Siha, Caski, and C33A cervical cancer cell lines (2–10 μM, 24–48 h) (ApexBio).
• Reversine treatment of murine myoblasts leads to dedifferentiation and altered lineage commitment (3 μM, 72 h) (Kaisari et al., 2019).
• In vivo, murine xenograft models receiving reversine (5–10 mg/kg, intraperitoneal, 21 days) exhibit significant tumor weight and volume reduction compared to controls, especially when co-administered with aspirin (100 mg/kg) (Kaisari et al., 2019).
• Reversine disrupts the Aurora kinase-dependent regulation of mitotic checkpoint complexes, impairing MCC disassembly and promoting apoptosis in mitotically arrested cancer cells (Kaisari et al., 2019).

Applications, Limits & Misconceptions

Reversine is a valuable tool in cancer research for interrogating mitotic regulation, cell cycle checkpoints, and apoptosis pathways. Its use extends to mechanistic studies of Aurora kinase function and as a model for combinatorial anti-tumor strategies. For additional mechanistic depth, see "Reversine and the Next Frontier in Aurora Kinase Inhibition"—this article provides comparative analysis and predictive modeling not covered in the present review.

Common Pitfalls or Misconceptions

• Reversine is not suitable for clinical or diagnostic use; it is strictly for research applications (ApexBio).
• Long-term storage of reversine solutions is discouraged due to instability; prepare fresh aliquots for each experiment (store solid at -20°C).
• Reversine is insoluble in aqueous buffers; DMSO or ethanol (with gentle warming and sonication) are required for dissolution.
• Effects observed in murine or in vitro models may not translate directly to human clinical outcomes.
• Off-target effects beyond Aurora kinases have been reported at higher concentrations (>10 μM); dose-response optimization is essential.

Workflow Integration & Parameters

Reversine is supplied as a solid and should be stored at -20°C in a desiccated environment. For experimental use, dissolve reversine in DMSO to a final concentration of ≥19.65 mg/mL or in ethanol at ≥6.69 mg/mL (with gentle warming and ultrasonic treatment). Working concentrations in cell-based assays typically range from 1–10 μM. Solutions should be freshly prepared and used immediately; avoid repeated freeze-thaw cycles. For in vivo studies, reversine is administered by intraperitoneal injection (5–10 mg/kg) and can be combined with agents such as aspirin for synergistic effects. For advanced protocols and troubleshooting, see "Reversine: Illuminating Aurora Kinase Checkpoints"—this article provides integrative checkpoint biology and practical workflow notes beyond this summary.

Conclusion & Outlook

Reversine is a potent, selective Aurora kinase inhibitor that enables precise dissection of mitotic checkpoint control, cell cycle progression, and apoptosis in cancer research. Its robust performance in both in vitro and in vivo models supports its continued use as a benchmarking tool in cell biology and oncology. Ongoing research will further elucidate its full spectrum of activity and potential in combination therapeutic strategies. For a forward-looking perspective on mitotic checkpoint modulation, see "Reversine and the Future of Mitotic Checkpoint Modulation"—this article expands upon translational applications and regulatory insights beyond the current review.